Sunitinib, developed and marketed as Sutent by Pfizer Inc and previously known as SU11248, is a small-molecule medicine which has to be administered orally and has been proven to be effective in blocking multiple receptor tyrosine kinases (RTKs). Sunitinib was the first cancer drug simultaneously approved for two different indications, namely renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Global advancement of technology and increasing prevalence of pancreatic cancer are the prime growth drivers of the global sunitinib malate market. Coupled with increasing awareness about pancreatic cancer in emerging economies such as China, India and others is expected to create new opportunities for the sunitinib malate market. However, higher cost of research and development, and high cost of sutent are the key restraints for the sunitinib malate market.
Geographically, North America dominates the
sunitinib malate market driven by best in class infrastructure, easy access to healthcare, higher awareness about pancreatic cancer, higher technological knowledge and higher spending by the citizens towards healthcare expenditure. North America was followed by Europe and Asia-Pacific as the second and third largest market for sunitinib malate market. Asia Pacific is projected to have the fastest growth, owing to rapidly developing medical infrastructure, increasing medical tourism, increased spending, and increasing awareness amongst population in developing nations such as China and India in this region.
This report identifies the global sunitinib malate market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to the sunitinib malate market.
This report segments the sunitinib malate market on the basis of cancer type and regional market as follows:
- This report on the sunitinib malate market is segmented on the basis of major cancer types which can be treated with sunitinib malate, some of the major cancer types covered in this report are as follows: Pancreatic Neuroendocrine Tumors (Pancreatic cancer), Gastrointestinal stromal tumor (GIST) and Kidney Cancer
- This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the Sunitinib Malate market. Some of the major companies’ profiles in detail are as follows: